

Imaging Criteria of Vulnerable Plaques

Akiko Maehara, MD

**Cardiovascular Research Foundation/
Columbia University Medical Center
New York City, NY**



Conflict of Interest Disclosure

- Akiko Maehara
 - Personal: Consultant for ACIST, Boston Scientific Corporation, Speaker for St Jude Medical
 - Cardiovascular Research Foundation: Boston Scientific Corporation

Causes of Coronary Thrombosis


Joner M
CRT2015

Lesions with acute thrombi



Erosion - Thrombus in the Absence of Rupture



Presence of Necrotic Core



MGH Multicenter OCT Registry (n=126)

Definite OCT-Erosion


Probable OCT-Erosion




Presence of attached thrombus overlying an intact and visualized plaque

- 1) Luminal surface irregularity without thrombus
- 2) Attenuation of underlying plaque by thrombus without superficial lipid or calcification immediately proximal or distal site

Lesion Morphology and Plaque Burden in Pathology



OCT Defined Underlying Plaque in ACS



Jia H, et al. JACC 2013;62:1748-58. Niccoli G et al. EHJ 2015; 36:1377-84. Wang L et al. EHJ 2015
 doi:10.1093/ehjc.jev105 Higuma T et al. JACC Interv 2015;8:1166-76. Saia JACC Img 2015; 8: 566-75.

Difference of Morphology





Plaque Rupture



No Rupture

Prevalence




ADAPT-DES VH-IVUS Comparison

	STEMI (n=167)	NSTEMI /UAP (n=217)	Stable CAD (n=292)	P-Value
Plaque Rupture	56%	36%	24%	<0.0001
VH-TCFA	65%	53%	44%	<0.0001
Ca-ThCFA	10%	19%	26%	<0.0001
Minimum lumen area (mm ²)	2.5±0.7	2.8±1.0	3.0±1.1	<0.0001
Plaque Burden at MLA (%)	80.3±12.3	76.5±10.1	74.0±10.5	<0.0001
Remodeling index	1.11±0.47	1.02±0.36	0.99±0.41	0.0002

Predictor of STEMI


With Plaque Rupture

Plaque Burden per 10%
Odds Ratio: 2.8 [1.6, 4.8]
 $p=0.0001$



Without Plaque Rupture

MLA per 1.0 mm²
Odds Ratio: 0.64 [0.44, 0.94]
 $p=0.022$



WHC STEMI/NSTEMI IVUS

Acute MI 2002-2005
N=1400, 67% NSTEMI

N=189 (14%)
Age ≥ 80

N=739 (53%)
Age < 65

N=472 (33%)
Age: 65-79

NSTEMI
71%

STEMI
29%

NSTEMI
63%

STEMI
37%

30 (71%)

12 (29%)

23 (44%)


29 (56%)

IVUS

IVUS Findings

	Age>80	Age<65	p-value
Thrombus	1 (2%)	7 (14%)	0.04
Calcified Plaque	57%	10%	0.009
Calcified Length, mm	5.5±2.9	3.5±2.8	0.006
Lesion Max Calcified Arc, °	199±91	115±71	<0.0001
Prox Ref Calcified Arc, °	90±50	65±23	0.2
Distal Ref Calcified Arc, °	68±30	49±18	0.4
MLA, mm ²	2.6±1.2	2.8±1.8	0.5
Remodeling Index, mm ²	0.85±0.2	1.03±0.2	0.0004

FAME 2: Landmark Analysis of Death or MI




Lesion morphology with angiographic DS>30% by OCT/IVUS

Angio DS	30-49%	50-69%	>70%
OCT			
Prevalence of TCFA	18% (58/325)	18% (40/227)	36% (33/91)
Fibrous cap thickness (µm)	57.0±6.6	56.0±7.5	49.0±9.2
Lipid arc (°)	214±56	209±55	204±59
Lipid length (mm)	9.4±4.6	10.5±5.5	9.6±4.5
IVUS			
Lumen area (mm ²)	5.8±2.4	4.5±2.1	3.2±2.3
Plaque burden (%)	58.1±8.4	67.5±9.4	80.1±7.4
Remodeling index	0.98±0.10	1.02±0.13	1.09±0.13



Large rupture with large thrombus






Erosion with small thrombus



Severe stenosis with small thrombus with or without erosion



A PROSPECT Case



The PROSPECT Trial

700 pts with ACS

UA (with ECGΔ) or NSTEMI or STEMI >24^o
undergoing PCI of 1 or 2 major coronary arteries
at up to 40 sites in the U.S. and Europe

Metabolic S.

- Waist circum
- Fast lipids
- Fast glu
- HgbA1C
- Fast insulin
- Creatinine

PCI of culprit lesion(s)

Successful and uncomplicated

Formally enrolled

Biomarkers

- Hs CRP
- IL-6
- sCD40L
- MPO
- TNFα
- MMP9
- Lp-PLA2
- others

PROSPECT: Multivariable Correlates of Non Culprit Lesion Related Events

Independent predictors of lesion level events by Cox Proportional Hazards regression



<u>Variable</u>	<u>HR [95% CI]</u>	<u>P value</u>
$PB_{MLA} \geq 70\%$	5.03 [2.51, 10.11]	<0.0001
VH-TCFA	3.35 [1.77, 6.36]	0.0002
$MLA \leq 4.0 \text{ mm}^2$	3.21 [1.61, 6.42]	0.001

Variables entered into the model: minimal luminal area (MLA) $\leq 4.0 \text{ mm}^2$; plaque burden at the MLA ($PB_{MLA} \geq 70\%$); external elastic membrane at the MLA ($EEM_{MLA} < \text{median} (14.1 \text{ mm}^2)$); lesion length $\geq \text{median} (11.2 \text{ mm})$; distance from ostium to MLA $\geq \text{median} (30.4 \text{ mm})$; remodeling index $\geq \text{median} (0.94)$; VH-TCFA

64 year old presents with STEMI in March 2012



Unstable angina October 2012






Methods

- Evaluated non-stented coronary segments for large LRP
 - defined as a $\max\text{LCBI}_{4\text{mm}} \geq 500$
- Patients followed for MACCE
 - Composite of all-cause mortality, recurrent ACS requiring revascularization, or acute cerebrovascular events
- Events related to previously stented segments were excluded
- All events adjudicated blinded to the NIRS-IVUS imaging


Large LRP
in
non-
stented
segment

Stented
segment
excluded
from
analysis





Large LRP by NIRS and MACCE



MACCE Rate
Large LRP 58.3%
vs
No large LRP 6.4%
($p < 0.001$)

ACS Requiring Revascularization
Large LRP 25.0%
vs
No large LRP 4.6%
($p < 0.001$)

How to Define Vulnerable Plaque? What Does It Mean?

- 1. Large amount of necrotic core with thin cap fibroatheroma causing plaque rupture with large thrombus**
- 2. Mild-severe plaque burden with pathological intimal thickening or early fibroatheroma causing plaque erosion with limited amount of thrombus. Prediction is difficult.**
- 3. Severe stenosis with any kind of underlying plaque causing limited amount of thrombus without rupture**
- 4. All together, vulnerable plaque should be defined as “large plaque burden, small lumen area, and TCFA”.**